Market Intelligence, Clinical Progress, and High-Purity Reagents for ALS, FTD, and Sarcoma Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FUS/TLS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FUS/TLS Full-Length & ALS Mutant Proteins High purity (>95%), Monomeric/Aggregate fractions available. Sequence Verified. |
View FUS/TLS Products |
| Gene Delivery | FUS/TLS ORF Lentivirus (WT & Mutants) R521C, R521H, P525L variants for stable cell line construction. Endotoxin Controlled. |
View FUS/TLS Products |
| Benchmark Ab | Anti-FUS/TLS Recombinant Antibody Sequence-verified rabbit monoclonal for IP/Western. |
View FUS/TLS Products |
| Validator | FUS/TLS siRNA Set For knockdown verification and specificity controls. |
View FUS/TLS Products |
| Related Target: TDP-43 | TARDBP Co-pathology RNA-binding protein in ALS/FTD. |
View TARDBP Products |
| Related Target: p62 | SQSTM1 Autophagy adaptor regulating stress granule clearance. |
View SQSTM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Phase Separation vs Aggregation Delineation | Monomeric protein fractions (>95% pure, SEC validated) for LLPS assays; Aggregate-prone mutant controls (R521C, P525L) included. |
| Mutant vs Wild-Type Selectivity Screening | Matched WT and ALS-mutant protein panel (R521C, R521H, P525L) with identical expression tags for direct comparative binding studies. |
| Intracellular Localization Validation | Lentivirus particles (CMV promoter) encoding FUS/TLS-WT and mutants with C-terminal GFP tags for nuclear import/cytoplasmic mislocalization tracking. |
| False Positives in Aggregation Inhibitors | Validated siRNA included for specificity checks; Sequence-verified antigens eliminate lot-to-lot variation artifacts. |
Live FUS/TLS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The FUS/TLS therapeutic landscape is bifurcated between neurodegeneration (ALS/FTD) and oncology (myxoid liposarcoma). In neurodegeneration, the field is pivoting from SOD1-targeted approaches toward the FUS/TLS and TDP-43 axis, driven by the understanding that gain-of-toxicity from cytoplasmic aggregation drives pathology. As first-generation antisense oligonucleotides (ASOs) advance for SOD1, FUS-targeted ASOs and small-molecule phase separation modulators are entering preclinical development. In oncology, targeting the FUS-CHOP fusion oncoprotein in liposarcoma represents a distinct mechanistic challenge requiring transcription factor disruption technologies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO | Ionis Pharmaceuticals, Biogen | FUS-ALS (Genetic) | Nuclear/Cytoplasmic localization assay (Need Lentivirus cell lines) |
| Small Molecule | Novartis, Denali Therapeutics, Aquinnah Pharmaceuticals | ALS/FTD | Liquid-Liquid Phase Separation (LLPS) inhibition assay (Need monomeric WT vs mutant proteins) |
| PROTAC/Degrader | Arvinas, Cullgen | FUS-CHOP Liposarcoma | Intracellular degradation validation (Need specific mutant recognition) |
| Gene Therapy | Spark Therapeutics (Roche) | Genetic ALS | Functional rescue assays (Need mutant proteins as pathological controls) |